Mycophenolate mofetil and azathioprine in chronic hypersensitivity pneumonitis Source: International Congress 2016 – Orphan diseases I Year: 2016
Safety and effectiveness of mycophenolate mofetil in interstitial lung diseases Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
Mycophenolate mofetil reduces alveolar inflammation and acute rejection and improves overall outcome after lung transplantation Source: Eur Respir J 2006; 28: Suppl. 50, 724s Year: 2006
A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression? Source: Eur Respir J, 57 (6) 2004354; 10.1183/13993003.04354-2020 Year: 2021
Use of mycophenolate mofetil for the treatment of hypersensitivity pneumonitis> Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020
Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016
Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis Source: Eur Respir J, 57 (3) 2002872; 10.1183/13993003.02872-2020 Year: 2021
Can mycophenolate mofetil 15 mg/kg/day attenuate experimental pulmonary fibrosis in rats? Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009
Results of switch from mycophenolate mofetil to azathioprin after lung transplantation Source: Eur Respir J 2004; 24: Suppl. 48, 178s Year: 2004
Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012
Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. A retrospective study Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017 Year: 2017
Pneumocystis jiroveci Pneumonia prophylaxis in patients treated with mycophenolate mofetil for interstitial lung disease Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021
Mycophenolate mofetil (MMF) rescue therapy in lung transplantation: results and pharmacokinetics Source: Eur Respir J 2002; 20: Suppl. 38, 348s Year: 2002
Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease Source: International Congress 2017 – Novel and old entities Year: 2017
Churg-Strauss syndrome treated with mycophenolate mofetil Source: Eur Respir J 2002; 20: Suppl. 38, 65s Year: 2002
Case series reporting the effectiveness of mycophenolate mofetil in treatment-resistant asthma Source: Eur Respir J 2013; 42: 1134-1137 Year: 2013
Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005
Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004
An observational study on effectiveness of azathioprine in treatment of interstitial lung disease secondary to connective tissue disease Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019